Niagen Bioscience Inc
NASDAQ:NAGEBiotechnology
Healthcare
$1.94 +3.31%
+$0.11 today
- Market cap
- $153.64M
- Beta
- 2.06
- P/E (TTM)
- 14.9
- EPS (TTM)
- $0.23
52W Low $3.35High $14.69
Volume 0.52M
Average 0.86M
Income Statement
Follow revenue through to earnings.
Revenue
$129.42M
FY 2025 · Annual
+29.9% YoYOperating Income
$14.30M
FY 2025 · Annual
+85.0% YoYNet Income
$17.38M
FY 2025 · Annual
+103.3% YoYIncome Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 67.45M | 72.05M | 83.57M | 99.6M | 129.42M |
| Cost of Revenue | 25.96M | 29.25M | 32.79M | 38.01M | 46.23M |
| Gross Profit | 41.49M | 42.8M | 50.78M | 61.59M | 83.19M |
| Gross Margin | 61.5% | 59.4% | 60.8% | 61.8% | 64.3% |
| Research & Development | 3.83M | 4.83M | 4.96M | 6.02M | 6.33M |
| Selling, General & Admin | 64.73M | 56.6M | 51.42M | 47.84M | 62.56M |
| Operating Expenses | 68.56M | 61.43M | 56.38M | 53.86M | 68.89M |
| Depreciation & Amortization | 1.63M | 1.88M | 1.71M | 1.48M | 1.45M |
| EBITDA | (25.45M) | (14.66M) | (3.23M) | 10.34M | 19.64M |
| EBITDA Margin | -37.7% | -20.3% | -3.9% | 10.4% | 15.2% |
| Operating Income | (27.07M) | (18.63M) | (5.6M) | 7.73M | 14.3M |
| Operating Margin | -40.1% | -25.9% | -6.7% | 7.8% | 11.0% |
| Interest Income | 0 | 3K | 661K | 1.13M | 2.13M |
| Interest Expense | 55K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (55K) | 2.09M | 661K | 1.13M | 3.9M |
| Income Before Tax | (27.13M) | (16.54M) | (4.94M) | 8.86M | 18.19M |
| Pre-Tax Margin | -40.2% | -23.0% | -5.9% | 8.9% | 14.1% |
| Income Tax Expense | 0 | 0 | 0 | 305K | 810K |
| Net Income | (27.13M) | (16.54M) | (4.94M) | 8.55M | 17.38M |
| Net Margin | -40.2% | -23.0% | -5.9% | 8.6% | 13.4% |
| EPS (Basic) | (0.40) | (0.24) | (0.07) | 0.10 | 0.22 |
| EPS (Diluted) | (0.40) | (0.24) | (0.07) | 0.11 | 0.20 |
| 67.19M | 68.92M | 70.54M | 85.42M | 79.18M | |
| 67.19M | 69.73M | 74.99M | 79.72M | 85.44M |
NAGE Earnings Waterfall · TTM
NASDAQ:NAGE · Revenue to Net Income
Key Ratios
EPS$0.22
Gross Margin64.3%
Net Margin14.3%
P/E Ratio42.5
P/S Ratio22.0
Analysis
$130.4M of revenue converted into $18.6M of net income for the selected period. Gross margin is 64.3% and net margin is 14.3%, showing how much revenue survives after costs and taxes. EPS is $0.22, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 8-K | Current report | Nov 4, 2026 |
How much revenue does NAGE generate?
Niagen Bioscience Inc (NAGE) reported $129.42M of revenue in fiscal 2025.
Is NAGE profitable?
Niagen Bioscience Inc (NAGE) reported $17.38M of net income, with a net margin of 13.4%.
Continue the stock analysis
Jump to another research area for this company.